Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 733.04M | 703.24M | 647.51M | 624.81M | 569.54M | 598.57M |
Gross Profit | 503.68M | 476.15M | 269.18M | 462.20M | 428.34M | 467.02M |
EBITDA | 475.39M | 412.61M | 311.81M | 323.35M | 166.21M | 417.96M |
Net Income | 182.33M | 126.71M | 13.76M | -77.61M | -113.26M | 138.42M |
Balance Sheet | ||||||
Total Assets | 5.33B | 5.30B | 5.39B | 5.75B | 5.97B | 5.99B |
Cash, Cash Equivalents and Short-Term Investments | 95.17M | 60.47M | 41.28M | 49.31M | 112.00M | 59.08M |
Total Debt | 1.76B | 2.44B | 2.45B | 2.70B | 2.39B | 2.37B |
Total Liabilities | 2.62B | 2.56B | 2.58B | 2.69B | 2.59B | 2.58B |
Stockholders Equity | 2.71B | 2.74B | 2.80B | 3.06B | 3.38B | 3.41B |
Cash Flow | ||||||
Free Cash Flow | 338.84M | 310.54M | 300.57M | 315.73M | 322.78M | 249.26M |
Operating Cash Flow | 338.84M | 310.54M | 300.57M | 315.73M | 356.39M | 354.85M |
Investing Cash Flow | -100.05M | -109.00M | 103.13M | -216.25M | -336.20M | -136.45M |
Financing Cash Flow | -179.44M | -181.56M | -410.30M | -161.71M | 30.14M | -202.11M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | $7.61B | 28.81 | 8.36% | 3.63% | 50.84% | 104.44% | |
79 Outperform | $3.67B | 24.68 | 10.49% | 4.62% | 6.87% | 7.23% | |
76 Outperform | $12.50B | 26.43 | 10.47% | 6.34% | 12.73% | 23.51% | |
74 Outperform | $4.70B | 25.81 | 6.66% | 6.14% | 6.89% | 240.70% | |
73 Outperform | $1.68B | 20.03 | 8.94% | 6.20% | 8.18% | -16.83% | |
70 Neutral | $7.25B | ― | -1.51% | 2.35% | 11.62% | ― | |
53 Neutral | $1.23B | 2.93 | -5.63% | 5.65% | -3.91% | -97.46% |
On August 5, 2025, Sabra Health Care REIT, Inc. entered into a new equity distribution agreement with several financial institutions to issue and sell common stock shares, aiming to raise up to $750 million. This move replaces a prior agreement from February 2023, which was terminated on the same date, and is intended to support the company’s financial strategies, including debt repayment and potential future investments.
The most recent analyst rating on (SBRA) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Sabra Healthcare REIT stock, see the SBRA Stock Forecast page.
In the second quarter of 2025, Sabra Health Care REIT reported a net income of $0.27 per diluted share and announced several strategic investments, including a $53 million acquisition of a senior housing property. The company also transitioned 21 senior housing properties to new operators, aiming to enhance asset value. Sabra closed a $500 million unsecured term loan to refinance existing debt, reducing interest costs. The company updated its 2025 earnings guidance, reflecting positive trends in Medicare and Medicaid reimbursement rates, which are expected to support its skilled nursing portfolio. Sabra’s liquidity stood at $1.2 billion as of June 30, 2025, and the company declared a quarterly dividend of $0.30 per share.
The most recent analyst rating on (SBRA) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Sabra Healthcare REIT stock, see the SBRA Stock Forecast page.
On July 30, 2025, Sabra Health Care REIT, Inc. and its subsidiaries entered into a $500 million unsecured credit agreement with several financial institutions, with the potential to increase borrowings to $1 billion. The agreement includes interest rate swaps that fix the SOFR portion of the interest rate, resulting in an effective rate of 4.64% through 2030. Additionally, Sabra redeemed its 5.125% Senior Notes due 2026 on July 31, 2025, at a cash redemption price of 100.575% of the principal, plus accrued interest. These financial maneuvers are expected to optimize Sabra’s capital structure and potentially enhance its financial flexibility.
The most recent analyst rating on (SBRA) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Sabra Healthcare REIT stock, see the SBRA Stock Forecast page.
On June 30, 2025, Sabra Health Care REIT, Inc. announced that its subsidiary, Sabra Health Care Limited Partnership, will redeem all $500 million of its outstanding 5.125% Senior Notes due 2026 on July 31, 2025. This redemption will be funded by issuing a $500 million term loan, and it will cease the accrual of interest on the Notes, impacting the company’s financial operations and potentially its market positioning.
The most recent analyst rating on (SBRA) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Sabra Healthcare REIT stock, see the SBRA Stock Forecast page.
On June 12, 2025, Sabra Healthcare REIT held its annual stockholders meeting where several key decisions were made. The stockholders elected seven directors to the board, ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for 2025, and approved the executive compensation plan, reflecting continued confidence in the company’s leadership and strategic direction.
The most recent analyst rating on (SBRA) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Sabra Healthcare REIT stock, see the SBRA Stock Forecast page.